Detection of blood biomarker in the patients' with Bevacizumab treated glioblastomas

• Project/Area Number: 16K20015
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Neurosurgery
• Research Institution: Kyushu University
• Principal Investigator: Kuga Daisuke 九州大学, 医学研究院, 助教 (40759932)
• Project Period (FY): 2016-04-01 – 2018-03-31
• Project Status: Completed (Fiscal Year 2017)
• Budget Amount: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000); Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000); Fiscal Year 2016: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
• Keywords: glioblastoma / liquid biopsy / 膠芽腫 / Glioblastom / bevacizumab / バイオマーカー

Outline of Final Research Achievements

The purpose of this study is to predict the clinical course, efficacy of treatment in the patients with Bevacizumab treated glioblastoma analyzing the cell free DNA from tumor cell in the patients' blood. However, we were not able to detect any mutation of target gene in the patients' blood, indicating cell free DNA was not released into the blood. Then we used the patients' CSF as alternative candidate. We were able to some genes which originated from tumor cell in the patients' CSF. These results imply that CSF may be a good candidate for liquid biopsy in the patients with GBM.

Research Products

• [Journal Article] Reclassification of 400 consecutive glioma cases based on the revised 2016WHO classification. (2018)
  • Author(s): Akagi Y, Yoshimoto K, Hata N, Kuga D, Hatae R, Amemiya T, Sangatsuda Y, Suzuki SO, Iwaki T, Mizoguchi M, Iihara K.
  • Journal Title: Brain tumor pathology Volume: 35 Issue: 2 Pages: 81-89
  • DOI: 10.1007/s10014-018-0313-4
  • Peer Reviewed
• [Journal Article] High-resolution melting and immunohistochemical analysis efficiently detects mutually exclusive genetic alterations of adamantinomatous and papillary craniopharyngiomas (2017)
  • Author(s): Yoshimoto Koji、Hatae Ryusuke、Suzuki Satoshi O.、Hata Nobuhiro、Kuga Daisuke、Akagi Yojiro、Amemiya Takeo、Sangatsuda Yuhei、Mukae Nobutaka、Mizoguchi Masahiro、Iwaki Toru、Iihara Koji
  • Journal Title: Neuropathology Volume: 38 Issue: 1 Pages: 3-10
  • DOI: 10.1111/neup.12408
  • Peer Reviewed
• [Journal Article] Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution. (2017)
  • Author(s): Yoshimoto K, Hatae R, Sangatsuda Y, Suzuki SO, Hata N, Akagi Y, Kuga D, Hideki M, Yamashita K, Togao O, Hiwatashi A, Iwaki T, Mizoguchi M, Iihara K.
  • Journal Title: Brain Tumor Pathol. Volume: 印刷中 Issue: 3 Pages: 103-112
  • DOI: 10.1007/s10014-017-0287-7
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status. (2016)
  • Author(s): Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Shono T, Mizoguchi M, Iihara K.
  • Journal Title: Onco Targets Ther. Volume: 10 Pages: 429-437
  • DOI: 10.2147/ott.s125587
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Insular primary glioblastomas with IDH mutations: Clinical and biological specificities. (2016)
  • Author(s): Hata N, Hatae R, Yoshimoto K, Murata H, Kuga D, Akagi Y, Sangatsuda Y, Suzuki SO, Iwaki T, Mizoguchi M, Iihara K.
  • Journal Title: Neuropathology Volume: 24 Issue: 3 Pages: 200-207
  • DOI: 10.1111/neup.12362
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] Deferred radiotherapy and upfront procarbazine-ACNU-vincristine administration for 1p19q codeleted oligodendroglial tumors are associated with favorable outcome without compromising patient performance, regardless of WHO grade. (2016)
  • Author(s): Hata N, Yoshimoto K, Hatae R, Kuga D, Akagi Y, Suzuki SO, Iwaki T, Shono T, Mizoguchi M, Iihara K.
  • Journal Title: Onco Targets Ther. Volume: 9 Pages: 7123-7131
  • DOI: 10.2147/ott.s115911
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Journal Article] A comprehensive analysis identifies BRAF hotspot mutations associated with gliomas with peculiar epithelial morphology. (2016)
  • Author(s): Hatae R, Hata N, Suzuki SO, Yoshimoto K, Kuga D, Murata H, Akagi Y, Sangatsuda Y, Iwaki T, Mizoguchi M, Iihara K.
  • Journal Title: Neuropathology Volume: 28 Issue: 3 Pages: 191-199
  • DOI: 10.1111/neup.12347
  • Peer Reviewed / Acknowledgement Compliant
• [Journal Article] Diagnostic Utility of Intravoxel Incoherent Motion MR imaging in Differentiating Primary Central Nervous System Lymphoma from Glioblastoma Multiforme (2016)
  • Author(s): .Yamashita K, Hiwatashi A, Togao O, et al.
  • Journal Title: J Magn Reson Imaging. Volume: 44(5) Issue: 5 Pages: 1256-1261
  • DOI: 10.1002/jmri.25261
  • Peer Reviewed / Open Access / Acknowledgement Compliant
• [Presentation] 膠芽腫におけるギリアデル留置後の再発形式および病理学的変化の検討 (2017)
  • Author(s): 空閑太亮、赤木洋二郎、秦暢宏、吉本幸司、溝口昌弘、鈴木諭、飯原弘二
  • Organizer: 第35回日本脳腫瘍病理学会
• [Presentation] Clinical significance of salvage surgery for recurrent IDH-mutant and 1p/19q codeleted oligodendroglial tumor (2017)
  • Author(s): 空閑太亮、秦暢宏、吉本幸司、波多江 龍亮、赤木洋二郎、溝口昌弘、飯原弘二
  • Organizer: The 14th meeting of the asian society for neuro-oncology
  • Int'l Joint Research
• [Presentation] IDH mutant, 1p/19q codeletd Oligodendroglial tumorの長期予後 (2016)
  • Author(s): 空閑太亮 秦暢宏 吉本幸司 波多江龍亮 赤木洋二郎 溝口昌弘 佐山徹郎 飯原 弘二
  • Organizer: 第34回日本脳腫瘍学会
  • Place of Presentation: 山梨県 甲府市